JeanMarie Guenot, the Chief Executive Officer of Amphivena Therapeutics, has recently announced that the Food and Drug Administration has accepted their application for an investigative trial of one of their drugs geared towards fighting cancer. Known as AMV564, the drug has been designed to work closely with the Amphivena Therapeutics’ proprietary antibodies.
As a part of the application’s acceptance, Dr. Guenot is now prepared to expand the company’s current product availability and introduce it to new patients. It is hoped that by increasing the scope of their trial, the company will be able to gather more information on the effectiveness of the drug and adapt its current metrics accordingly. As of right now, the drug is currently being marketed towards patients that have acute myeloid leukemia.
For the first stage of this new trial, Amphivena Therapeutics will be studying the safety of rising doses in its patients. After a rigorous evaluation of the data from this trial, the company will then move on to reviewing its effectiveness in treating tumors and preventing their development. Through this process, Dr. Guenot and her leadership staff will be able to design specific measures that take into account the maximum safe dose for a patient and ensure that there are no unnecessary side effects. With this information, Amphivena Therapeutics will be able to seamlessly transition into the second phase of their program, where they put the drug through even more rigorous testing.
While Amphivena Therapeutics is known for working tirelessly to come up with new and innovative ways to combat cancer, this news really serves as further evidence that Dr. Guenot is not letting her Ph.D. go to waste. By working closely with research personnel to develop new methods of treating diseases, and then working with the financial side to ensure that they have the funding they need, JeanMarie Guenot has managed to transform her business into a well-respected outlet for developing drugs to combat cancer. Newson6 covered one of the brilliant moves JeanMarie Guenot has done in the past in their story “Maverick Therapeutics and Takeda Announce Five-year Collaboration to Advance T-Cell Engagement Therapies”.